REGN vs. VRTX
Compare and contrast key facts about Regeneron Pharmaceuticals, Inc. (REGN) and Vertex Pharmaceuticals Incorporated (VRTX).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: REGN or VRTX.
Correlation
The correlation between REGN and VRTX is 0.39, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
REGN vs. VRTX - Performance Comparison
Loading data...
Key characteristics
REGN:
-1.21
VRTX:
-0.02
REGN:
-1.80
VRTX:
0.29
REGN:
0.78
VRTX:
1.04
REGN:
-0.71
VRTX:
0.10
REGN:
-1.22
VRTX:
0.26
REGN:
32.36%
VRTX:
9.11%
REGN:
32.05%
VRTX:
28.58%
REGN:
-91.81%
VRTX:
-91.77%
REGN:
-50.48%
VRTX:
-15.11%
Fundamentals
REGN:
$63.16B
VRTX:
$111.55B
REGN:
$39.37
VRTX:
-$3.83
REGN:
1.26
VRTX:
2.59
REGN:
4.48
VRTX:
10.05
REGN:
2.15
VRTX:
6.76
REGN:
$14.09B
VRTX:
$11.09B
REGN:
$11.96B
VRTX:
$9.54B
REGN:
$4.98B
VRTX:
-$228.00M
Returns By Period
In the year-to-date period, REGN achieves a -16.46% return, which is significantly lower than VRTX's 8.93% return. Over the past 10 years, REGN has underperformed VRTX with an annualized return of 1.68%, while VRTX has yielded a comparatively higher 13.11% annualized return.
REGN
-16.46%
8.20%
-21.37%
-38.52%
0.63%
1.68%
VRTX
8.93%
-9.72%
-5.81%
-0.45%
8.75%
13.11%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
REGN vs. VRTX — Risk-Adjusted Performance Rank
REGN
VRTX
REGN vs. VRTX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and Vertex Pharmaceuticals Incorporated (VRTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
REGN vs. VRTX - Dividend Comparison
REGN's dividend yield for the trailing twelve months is around 0.15%, while VRTX has not paid dividends to shareholders.
| TTM | |
|---|---|
REGN Regeneron Pharmaceuticals, Inc. | 0.15% |
VRTX Vertex Pharmaceuticals Incorporated | 0.00% |
Drawdowns
REGN vs. VRTX - Drawdown Comparison
The maximum REGN drawdown since its inception was -91.81%, roughly equal to the maximum VRTX drawdown of -91.77%. Use the drawdown chart below to compare losses from any high point for REGN and VRTX. For additional features, visit the drawdowns tool.
Loading data...
Volatility
REGN vs. VRTX - Volatility Comparison
Regeneron Pharmaceuticals, Inc. (REGN) has a higher volatility of 17.04% compared to Vertex Pharmaceuticals Incorporated (VRTX) at 13.52%. This indicates that REGN's price experiences larger fluctuations and is considered to be riskier than VRTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
REGN vs. VRTX - Financials Comparison
This section allows you to compare key financial metrics between Regeneron Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
REGN vs. VRTX - Profitability Comparison
REGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.56B and revenue of 3.03B. Therefore, the gross margin over that period was 84.7%.
VRTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported a gross profit of 2.41B and revenue of 2.77B. Therefore, the gross margin over that period was 86.9%.
REGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Regeneron Pharmaceuticals, Inc. reported an operating income of 591.70M and revenue of 3.03B, resulting in an operating margin of 19.5%.
VRTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported an operating income of 630.10M and revenue of 2.77B, resulting in an operating margin of 22.8%.
REGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Regeneron Pharmaceuticals, Inc. reported a net income of 808.70M and revenue of 3.03B, resulting in a net margin of 26.7%.
VRTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Vertex Pharmaceuticals Incorporated reported a net income of 646.30M and revenue of 2.77B, resulting in a net margin of 23.3%.